NEW YORK (360Dx) – BioMérieux said today it has signed a deal to commercialize Banyan Biomarkers' tests for diagnosing traumatic brain injuries (TBI).

Under the terms of the agreement, BioMérieux will make a $7 million equity investment in Banyan in exchange for rights to commercialize Banyan's TBI tests for global use as in vitro diagnostics on BioMérieux's VIDAS immunoassay platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.